News | Proton Therapy | September 21, 2015

IBA to Install Latin America’s First Proton Therapy Center in Argentina

Facility to begin treating patients at the end of 2018

September 21, 2015 — IBA (Ion Beam Applications SA) announced that it has signed a contract with the company INVAP for the installation of a proton therapy center at the Instituto de Oncologia Angel Roffo hospital in Buenos Aires, Argentina.

IBA will equip the new center with its ProteusPlus system, including one gantry treatment room with next-generation pencil beam scanning capability and one research and development room. The contract will also include an operation and maintenance agreement. The equipment and services that will be supplied by IBA are worth between EUR 35 and 40 million to IBA.

This first proton therapy center to be installed in Latin America is part of the implementation of the Nuclear Medicine National Plan of the Argentine Ministry of Federal Planning, Public Investment and Services, together with the Ministry of Health and the National Atomic Energy Commission (CNEA). The Nuclear Medicine National Plan is a unique government plan of investment in infrastructure and equipment designed to ensure free access to the highest standards in prevention, treatment, research and training in nuclear medicine and oncology. It is expected that the center will treat its first patient at the end of 2018.

The Argentine Minister of Federal Planning, Public Investment and Services, Julio De Vido, commented: "Bringing an innovative new cancer center closer to the people has the objective to give better chances to fight this severe disease. Argentina is the first country in Latin America to have access to this unique medical technology which will be beneficial for the health of patients in the country.”

For more information: www.iba-worldwide.com

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
The IBA Proteus Plus

The IBA Proteus Plus.

Feature | Proton Therapy | September 08, 2017 | By Jeff Zagoudis
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init